Please login to the form below

Not currently logged in
Email:
Password:

RCC

This page shows the latest RCC news and features for those working in and with pharma, biotech and healthcare.

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

The approval covers patients with intermediate- and poor-risk RCC, which covers around 75-80% of those diagnosed with the advanced form of the disease, according to BMS. ... RCC is the most common type of kidney cancer in adults, accounting for around 90%

Latest news

  • Pfizer’s plans for Inlyta go awry with failed adjuvant trial Pfizer’s plans for Inlyta go awry with failed adjuvant trial

    Pfizer’s hopes of reversing the decline of its renal cell carcinoma (RCC) treatment Inlyta have taken a knock with a failed phase III trial in patients with less advanced disease. ... Moreover, Pfizer’s own first-line RCC drug - Sutent (sunitinib) -

  • $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

    The prompt for the new deal seems to be encouraging results from the combination of Lenvima and Keytruda in the RCC cohort of the KEYNOTE-146 trial, with the duo achieving ... He added there was “strong scientific evidence”behind the combination,

  • BMS pens massive $3.6bn deal for Nektar cancer immunotherapy BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

    Pivotal trials in RCC and melanoma are due to start before the end of the year. ... RCC and NSCLC, and the scale of this expanded agreement suggests that preliminary data coming out of those projects is looking good.

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    NICE backs EUSA's RCC treatment Fotivda. The UK’s cost-effectiveness watchdog recommends its first-line use. ... EUSA Pharma has won NICE backing for Fotivda (tivozanib) as a first-line treatment for advanced renal cell carcimona (RCC).

  • Roche unveils data for Tecentriq/Avastin combo in kidney cancer Roche unveils data for Tecentriq/Avastin combo in kidney cancer

    The trial involved previously untreated patients with inoperable locally-advanced or metastatic renal cell carcinoma (RCC) whose tumours express the PD-L1 biomarker and will be presented at the American Society ... Bristol-Myers Squibb’s Opdivo

More from news
Approximately 9 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Although marketed as the orphan drug Cometriq for thyroid neoplasms, it’s as Cabometyx in renal cell carcinoma (RCC) where the firm views real potential. ... Approved in Europe as a treatment for advanced RCC, Cabometyx won backing from NICE at its

  • Charting a course for expansion Charting a course for expansion

    I think these is some really game-changing data for first-line and second-line RCC patients.”. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics